Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | FPR2 | P25090 | 5/20 | 0.34 |
| ▸ | MGLL | Q99685 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8945323 | 0.99 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3FPR2MGLL | |
| SCHEMBL18718438 | 0.96 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3FPR2MGLL | |
| SCHEMBL18718442 | 0.96 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3FPR2MGLL | |
| SCHEMBL18718432 | 0.95 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3FPR2MGLL | |
| SCHEMBL8945609 | 0.93 | FPR2 (0.33) | SLC6A2SLC6A4SLC6A3FPR2NAAA | |
| SCHEMBL18718420 | 0.93 | FPR2 (0.38) | SLC6A2SLC6A4SLC6A3FPR2MGLL | |
| SCHEMBL8945032 | 0.93 | FPR2 (0.36) | SLC6A2SLC6A4SLC6A3FPR2NAAA | |
| SCHEMBL8945748 | 0.92 | FPR2 (0.35) | FPR2 | |
| SCHEMBL8945459 | 0.92 | FPR2 (0.33) | FPR2 | |
| SCHEMBL8945229 | 0.92 | FPR2 (0.35) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | SLC6A2 2317/4885SLC6A4 901/4885SLC6A3 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.